Prostatic artery embolization is a minimally invasive procedure used in the treatment of benign prostatic hyperplasia. It involves blocking the blood vessels that supply the prostate gland using small particle injections, thereby reducing prostate size and relieving urinary symptoms. The procedure offers advantages over transurethral resection of the prostate such as quicker recovery time, reduced complications, and higher retreatment success rates. Prostatic artery embolization is increasingly being adopted as a first line therapy for benign prostatic hyperplasia, especially in older patients who are unfit for surgery.

The global Prostatic Artery Embolization Market is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics: The growth of the prostatic artery embolization market is majorly driven by the increasing prevalence of benign prostatic hyperplasia among aging men. It has been estimated that nearly 50% of men in their 50s and up to 90% in their 80s and 90s suffer from some degree of benign prostatic hyperplasia worldwide. Rising awareness about the benefits of minimally invasive treatments such as prostatic artery embolization over transurethral resection of the prostate is further fueling the adoption of the procedure. Prostatic artery embolization significantly reduces recovery time and morbidity compared to surgery, while achieving similar clinical outcomes. This factor is positively impacting the market growth.

SWOT Analysis

Strength: Prostatic Artery Embolization is a minimally invasive treatment option for enlarged prostate that causes urinary problems. It does not require cutting or removal of prostate tissue. The procedure allows rapid recovery time compared to traditional surgery. Patients can usually go home the same day and return to normal activities within a few days.

Weakness: Prostatic Artery Embolization is a relatively new procedure and long term outcomes are not well established. There is a learning curve for interventional radiologists to perform the procedure. Some patients may still require additional treatment after the procedure.

Opportunity: The aging population and high prevalence of Benign Prostatic Hyperplasia means there is a large patient base that can benefit from Prostatic Artery Embolization. As the procedure gets more popular, technology and techniques will improve making it more accessible. Establishing long term safety and effectiveness data can increase adoption over traditional surgical options.

Threats: Traditional surgical treatments like Transurethral Resection of the Prostate are well established with decades of clinical evidence and physician familiarity. Patients may prefer the conventional approach or be reluctant to try a newer minimally invasive option. Insurance coverage and reimbursement for Prostatic Artery Embolization needs to improve for it to become a widely used first line treatment.

Key Takeaways

The global Prostatic Artery Embolization Market Share is expected to witness high growth over the forecast period of 2023 to 2030 supported by an aging population susceptible to Benign Prostatic Hyperplasia. The global Prostatic Artery Embolization Market is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

The North American region currently dominates the market due to early adoption of the procedure and favorable reimbursement policies. Advancements in microcatheters and imaging technologies have made the procedure easier to perform boosting its popularity in major markets. The Asia Pacific region is expected to see rapid adoption of Prostatic Artery Embolization driven by rising medical tourism as well the growing healthcare infrastructure and spending power in countries like China, India and Japan. As more interventional radiologists gain expertise in Prostatic Artery Embolization, it has the potential to become a major treatment alternative to surgery especially in developing economies where the aging population is surging.

Key players: Key players operating in the Prostatic Artery Embolization market are Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc.

For more insights, read- https://cmiinfonest.blogspot.com/2023/12/prostatic-artery-embolization-market.html